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Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires — CONICET, Buenos Aires, ArgentinaExtreme genetic variability is the hallmark of HIV‐1 infection and it and clinical data to better understand the complexity of this phenome-
represents amajor challenge for antiviral treatment and vaccine develop-
ment. HIV‐1 group M dominates the global pandemic. Nine subtypes, 68
circulating recombinant forms (CRF) and countless unique recombinant
forms (URF) were describedwithin this group (Los Alamos HIV database,
www.hiv.lanl.gov). This genetic diversity not only affects viral epidemiol-
ogy but it is also linked to themechanisms used by the virus to escape the
patients' natural humoral and cellular immune responses as well as anti-
retroviral drug's action, thus precluding viral control. As a result, monitor-
ing the genetic diversity of HIV‐1 and understanding its consequences on
viral ﬁtness is crucial to control the spread of the epidemic.
Intersubtype genomic recombination is one of themainmechanisms
that allow achieving such a high diversity level. Indeed, CRFs account for
about 10–20% of all newHIV‐1 infectionswhile URFs are responsible for
over 30% of infections in regionswhere two ormore subtypes cocirculate,
clearly contributing to HIV‐1 evolution and adaptation to the human
population (Tebit and Arts, 2011). As such, this phenomenon has
been addressed by several groups and through different means
and many (confronting) hypothesis co‐exist today on the “biological
advantage” (if any) of CRFs over parental subtypes.
In an effort to understand the increasing prevalence of CRFs in
particular regions of the world, many researchers initiated the study
of the in vitro activity of isolated proteins (Nef, Vpu, Tat) or genomic re-
gions (LTR) derived from CRFs, in comparison to the activity of the pro-
teins/regions derived from the parental subtypes (Woollard et al., 2014;
De Candia et al., 2013; Turk et al., 2006, 2009). Otherswent one step fur-
ther and analyzed the ex vivo replicative ﬁtness of CRFs (Rubio et al.,
2014; Njai et al., 2006). Many of these reports suggest improved biolog-
ical capacities of CRFs compared to the parental subtypes. However, the
in vitro activity of a protein or even the viral ﬁtness measured ex vivo
are not necessarily correlated directly to the replication capacity within
a subject, its rate of disease progression or, even less, with the dynamic
of the epidemic at the population level. Conversely, other authors postu-
late a different scenario: preferential spread of less ﬁt viral variants (i.e.,
less pathogenic) due to increased transmission opportunities favored by
longer periods of asymptomatic infection. Only just a few studies dealt
with the challenge of providing, altogether, virological, epidemiologicalDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.01.015.
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2014).
In this issue of EBioMedicine, Kouri and colleagues (Kouri et al., 2015)
report results of their study on a Cuban cohort of HIV‐1‐infected indi-
viduals aimed at comparatively analyzing parameters that could
determine an increasing trend of HIV‐1 infected individuals showing
extremely rapid progression rates. The researchers used epidemiologi-
cal, clinical, virological, and immunological approaches to establish
putative correlates of disease progression. Several factors were found
to be statistically related to the rapid progressor condition. Among
them, it is worth highlighting the ﬁnding that all patients infected
with CRF19_cpx belonged to the group of rapid progressors. This CRF
is a complex recombinant between subtypes D, A and G, apparently cir-
culating exclusively in Cuba (although of African origin) and that it is
now reported in clear association with differential rates of diseases pro-
gression. Their ﬁndings are very interesting since they represent a prog-
ress in depicting genomic recombination as amechanism to gain ﬁtness.
Moreover, the study combines clinical follow‐up, virological characteri-
zation of CRF19_cpx and immunological approaches to provide poten-
tial explanations to the faster progression.
Reports like the one of Kouri and collaborators certainly contribute
to our understanding of the forces that drive HIV diversity. However,
there exist a myriad of other factors that may be also acting and that
are hard to include in these kinds of studies: founder effects, host re-
striction factors, transmission efﬁciency and social/behavioral/cultural/
geographical components may be all affecting differential spread of
HIV variants. Certainly, it is a ﬁeld that deserves and guarantees further
research aimed not only to comprehend viral diversity and spread but
also to assist in monitoring the epidemics, in monitoring and treating
the infection in those affected individuals, and in vaccine design and
development.
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